Group 1 - Company SciGen Pte. Ltd., a wholly-owned subsidiary of Yifan Pharmaceutical, has received approval from the Health Sciences Authority (HSA) of Singapore for the marketing registration of its pharmaceutical product, Norepinephrine SciGen, a concentrated solution for injection [1] - The product is indicated for the management of severe acute hypotension in adults and was approved domestically in March 2023, with the registration application submitted to HSA in December 2023 [1] - The approval supports the company's strategy for "full-category, multi-region" international expansion, with domestic production lines receiving international certification [1] Group 2 - The approval is not expected to have a significant short-term impact on the company's operating performance, but successful commercialization in the future could yield positive effects [1] - The operational situation may be influenced by overseas policies and exchange rate fluctuations, indicating some uncertainty for investors [1]

Core Viewpoint - Company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its pharmaceutical product, concentrated solution of racemic norepinephrine for injection, which is intended for the management of severe acute hypotension in adults [1] Group 1 - The product is specifically designed to control blood pressure levels in adults experiencing severe acute hypotension [1] - The approval marks a significant milestone for the company's expansion into the Singapore market [1]

Core Viewpoint - The company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its chemical drug, racemic norepinephrine injection solution, which is intended for the treatment of severe acute hypotension in adults [1] Group 1 - The company's subsidiary, SciGen Pte. Ltd., is responsible for the newly approved product [1] - The approved product is specifically designed to control blood pressure levels in adults experiencing severe acute hypotension [1]

Core Viewpoint - The company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its chemical drug, racemic norepinephrine injection solution, which is intended for the treatment of severe acute hypotension in adults [1] Group 1 - YiFan Pharmaceutical's wholly-owned subsidiary, SciGen Pte. Ltd., has been granted a market registration approval by HSA [1] - The approved product, racemic norepinephrine injection solution, is used for blood pressure control in adults experiencing severe acute hypotension [1] - The drug is designed to elevate blood pressure levels in critical situations [1]